No data available.
Please log in to see this content.
You have no subscription access to this content.
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.
Recommendations of the American Association of Physicists in Medicine on interstitial source calibration and dosimetry: Implications for dose specification and prescription
1.F. Williamson, B. M. Coursey, L. A. DeWerd, W. F. Hanson, R. Nath, and G. Ibbott, “Guidance to users of Nycomed Amersham and North American Scientific, Inc. I-125 Interstitial Sources: Dosimetry and calibration changes: Recommendation of the American Association of Physicists in Medicine Radiation Therapy Committee Ad Hoc Subcommittee on Low-Energy Seed Dosimetry,” Med. Phys. 26, 570–573 (1999).
2.R. Nath, L. L. Anderson, G. Luxton, K. A. Weaver, J. F. Williamson, and A. S. Meigooni, “Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43,” Med. Phys. 22, 209–234 (1995).
3.A. S. Meigooni, S. Sabnis, and R. Nath, “Dosimetry of palladium-103 brachytherapy sources for permanent implants,” Endocurietherapy/Hyperthermia Oncology 6, 107–117 (1990).
4.S.-T. Chiu-Tsao and L. L. Anderson, “Thermoluminescent dosimetry for seeds (model 200) in solid water phantom,” Med. Phys. 18, 449–452 (1991).
5.R. Loevinger, “Wide-angle free-air chamber for calibration of low-energy brachytherapy sources,” Med. Phys. 20, 907(abstract) (1993)
6.S. M. Seltzer, P. J. Lamperti, R. Loevinger, C. G. Soares, and J. T. Weaver, “New NIST air-kerma strength standards for I-125 and Pd-103 brachytherapy seeds (abstract),” Med. Phys. 25, 170 (1998).
7.S. M. Seltzer and P. J. Lamperti, Status of NIST Primary Standards for and Therapy Seeds Based on the Wide-Angle Free-Air Chamber (WAFAC): Proceedings of a CIRMS Workshop, National Institute of Standards and Technology, 1999.
8.B. M. Coursey, Model 200 Air-Kerma Calibration, personal communication, November 1999, National Institutes of Standards and Technology, Ionizing Radiation Division, Gaithersburg, MD.
9.M. C. Jacobs, letter to its customers, Personal Communication, 15 October 1997, Theragenics Corporation.
10.T. Robin and J. Rodgers, Theragenics Cd-109 Source Change History—Theraseed® Model 200, personal communication, 30 August 1999, Theragenics Corporation, Buford, GA.
11.Z. Li, “Monte Carlo calculations and experimental measurements of dosimetry parameters of a new Pd-103 source,” Report to North American Scientific, Inc., Radiation Oncology, University of Florida, 1999.
12.R. E. Wallace and J. J. Fan, “Dosimetric characterization of a new design brachytherapy source,” Med. Phys. 26, 2465–2470 (1999).
13.R. Nath, N. Yue, K. Shahnazi, and P. J. Bongiorni, “Measurement of dose-rate constant for seeds with air-kerma strength calibration based upon a primary national standard,” Med. Phys. 27, 655–658 (2000).
14.J. F. Williamson, “Monte Carlo modeling of the transverse-axis dose distribution of the Model 200 interstitial brachytherapy source,” Med. Phys. 27, 643–654 (2000).
15.T. P. Loftus, “Exposure Standardization of Iodine-125 Seeds Used for Brachytherapy,” J. Res. Natl. Bur. Stand. 89, 295–303 (1984).
16.S. Y. F. Chu, L. P. Ekström, and R. B. Firestone, “WWW Table of Radioactive Isotopes, database version 2/28/99 from URL http://nucleardata.nuclear.lu.se/nucleardata/toi/”
17.J. F. Williamson, B. M. Coursey, L. A. DeWerd, W. F. Hanson, R. Nath, M. J. Rivard, and G. Ibbott, “On the use of apparent activity for treatment planning of and interstitial brachytherapy sources: Recommendations of the American Association of Physicists in Medicine Radiation Therapy Committee Subcommittee on Low-Energy Brachytherapy Source Dosimetry,” Med. Phys. 26, 2529–2530 (1999).
18.E. E. Furhang and L. L. Anderson, “Functional fitting of interstitial brachytherapy dosimetry data recommended by AAPM Radiation Therapy Committee Task Group 43,” Med. Phys. 26, 153–160 (1999).
19.K. Weaver, “Anisotropy functions for and sources,” Med. Phys. 25, 2271–2278 (1998).
20.W. S. Bice, B. R. Prestidge, J. J. Prete, and D. F. Dubois, “Clinical impact of implementing AAPM Task Group 43 on permanent prostate brachytherapy using I-125,” Int. J. Radiat. Oncol., Biol., Phys. 40, 1237–1241 (1998).
21.M. Dattoli, K. Wallner, R. Sorace, J. Koval, J. Cash, R. Acosta, C. Brown, J. Etheridge, M. Binder, R. Brunelle, N. Kirwan, S. Sanchez, D. Stein, and S. Wasserman, “ brachytherapy and external beam irradiation for clinically-localized, high-risk prostatic carcinoma,” Int. J. Radiat. Oncol., Biol., Phys. 35, 875–879 (1996).
22.R. G. Stock, N. N. Stone, J. K. DeWyngaert, P. Lavagnini, and P. D. Unger, “Prostate specific antigen findings and biopsy results following interactive ultrasound-guided transperineal brachytherapy for early stage prostate carcinoma,” Cancer 77, 2386–2392 (1996).
23.L. L. Anderson, J. V. Moni, and L. B. Harrison, “A nomograph for permanent implants of palladium-103 seeds,” Int. J. Radiat. Oncol., Biol., Phys. 27, 129–135 (1993).
Data & Media loading...
Article metrics loading...
Full text loading...